Pharmaceutical Industry Related Content

The Joint Committee on Vaccination and Immunisation (JCVI) has advised that all under 40s should be offered an alternative to the Oxford/AstraZeneca vaccine following blood clot risk.

A new study has revealed that new medicines and vaccines approved for use in the United States are often unavailable in countries that helped to develop them.

Health Secretary Matt Hancock has announced that vaccines tailored to tackle COVID-19 variants will be fast-tracked through new state-of-the-art labs.

A combination of remdesivir and drugs for hepatitis C virus (HCV) have presented strong effectiveness against COVID-19 in a new study.

Here, Evolve Ltd’s Managing Director, Christopher Busuttil Delbridge, takes us progressively deeper into what it takes to ensure regulatory compliance for Medical Cannabis.

We spoke with Dr Matthew Duchars, CEO of the UK’s first dedicated Vaccines Manufacturing and Innovation Centre (VMIC), about their work not only to provide an integral response to COVID-19, but as a centre of excellence advancing the vaccine sector on a global scale.

The April 2021 edition of Open Access Government speaks about government policy issues globally, like COVID-19, health & social care, research & innovation, finance, digital transformation, agriculture, environment and energy.

We spoke with Tony Cecchin, Vice President and General Manager of Global Supplies at Zebra Technologies and President of Temptime Corporation, and Chris Caulfield, Vice President of Temptime Operations about their work supporting front-line workers and easing the shipment of medical products through the supply chain.

Rick Clayton, Technical Director, AnimalhealthEurope, unpacks Benchmarking Regulatory systems governing veterinary medicines in this the first of a series of three articles.

Dr Ash Ramzan, Founder and Principal Consultant, Woodley BioReg Limited, turns the spotlight on falsified medicines in this pharmaceuticals focus.

Professor Luis Diestre discusses the research and findings of his European Research Council funded Illegal Pharma Project, focussing on the ever popular market for counterfeit pharmaceuticals.

Dr. Christian Löfke, researcher and product developer at BioBloom in Austria explains the potential of CBD and cannabinoids for skin care.

David Hardstaff of BCL’s Cannabis Law & Regulatory team considers the success of the UK’s legalisation of medicinal cannabis products.

Michael Morrison, Senior Researcher in Social Science at the University of Oxford, illustrates the importance of emerging biomedical innovations in the UK.

Ruth Smith CEO of Active Care Group and its Christchurch Group division discusses the new highly virulent variant of COVID, vaccinations, and infection prevention and control (IPC).

The European Union has allocated an additional €500 million to the COVAX facility, bringing its total contribution to €1 billion.

Researchers have found that an existing heart failure drug can improve the symptoms associated with postural orthostatic tachycardia syndrome.

The EU drugs agency explores the impact of COVID-19 on drug markets, use and services in the European neighbourhood partnership countries.

Rick Brar, CEO & Chairman of Brains Bioceutical Corp. explores the landscape of medical cannabis in the UK and the future direction of the industry.

The UK Government and vaccine manufacturer CureVac have partnered to rapidly develop new vaccines in response to new COVID-19 virus variants.